Pacer Advisors Inc. Has $6.31 Million Stock Position in ANI Pharmaceuticals, Inc. $ANIP

Pacer Advisors Inc. boosted its position in shares of ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) by 1,821.1% in the 4th quarter, HoldingsChannel reports. The firm owned 79,919 shares of the specialty pharmaceutical company’s stock after buying an additional 75,759 shares during the period. Pacer Advisors Inc.’s holdings in ANI Pharmaceuticals were worth $6,309,000 at the end of the most recent reporting period.

Other large investors have also recently added to or reduced their stakes in the company. Advisors Asset Management Inc. bought a new position in shares of ANI Pharmaceuticals in the first quarter valued at approximately $28,000. Hantz Financial Services Inc. increased its holdings in ANI Pharmaceuticals by 70.3% during the 4th quarter. Hantz Financial Services Inc. now owns 603 shares of the specialty pharmaceutical company’s stock valued at $48,000 after purchasing an additional 249 shares in the last quarter. Kemnay Advisory Services Inc. bought a new position in ANI Pharmaceuticals in the 4th quarter valued at $48,000. State of Wyoming acquired a new position in ANI Pharmaceuticals in the second quarter worth $50,000. Finally, Mirae Asset Global Investments Co. Ltd. grew its holdings in shares of ANI Pharmaceuticals by 30.2% during the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,091 shares of the specialty pharmaceutical company’s stock worth $86,000 after purchasing an additional 253 shares during the last quarter. 76.05% of the stock is owned by institutional investors.

ANI Pharmaceuticals Price Performance

ANI Pharmaceuticals stock opened at $79.49 on Monday. The business’s 50-day simple moving average is $80.13 and its 200 day simple moving average is $79.30. The company has a quick ratio of 2.52, a current ratio of 3.12 and a debt-to-equity ratio of 1.06. The stock has a market cap of $1.81 billion, a price-to-earnings ratio of 20.12 and a beta of 0.44. ANI Pharmaceuticals, Inc. has a 12-month low of $62.60 and a 12-month high of $99.50.

ANI Pharmaceuticals (NASDAQ:ANIP) last announced its quarterly earnings data on Friday, May 8th. The specialty pharmaceutical company reported $2.05 earnings per share for the quarter, topping the consensus estimate of $1.28 by $0.77. The firm had revenue of $237.46 million during the quarter, compared to analysts’ expectations of $207.63 million. ANI Pharmaceuticals had a return on equity of 27.51% and a net margin of 9.98%.The company’s quarterly revenue was up 20.5% compared to the same quarter last year. During the same period in the previous year, the business posted $1.70 EPS. ANI Pharmaceuticals has set its FY 2026 guidance at 9.190-9.690 EPS. As a group, research analysts anticipate that ANI Pharmaceuticals, Inc. will post 8.07 earnings per share for the current year.

Insiders Place Their Bets

In other ANI Pharmaceuticals news, Director Thomas Haughey sold 2,000 shares of the firm’s stock in a transaction that occurred on Monday, June 8th. The shares were sold at an average price of $80.88, for a total value of $161,760.00. Following the transaction, the director directly owned 38,878 shares of the company’s stock, valued at approximately $3,144,452.64. This trade represents a 4.89% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Stephen P. Carey sold 3,312 shares of the company’s stock in a transaction on Friday, June 5th. The shares were sold at an average price of $80.00, for a total transaction of $264,960.00. Following the sale, the chief financial officer owned 180,393 shares of the company’s stock, valued at $14,431,440. The trade was a 1.80% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 79,016 shares of company stock valued at $6,195,991 over the last three months. 8.10% of the stock is owned by insiders.

Analysts Set New Price Targets

A number of research firms recently issued reports on ANIP. Wall Street Zen raised ANI Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a report on Saturday, May 9th. Weiss Ratings reaffirmed a “hold (c+)” rating on shares of ANI Pharmaceuticals in a research note on Monday, June 1st. Finally, Zacks Research cut shares of ANI Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Thursday, May 14th. Five investment analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $107.33.

About ANI Pharmaceuticals

ANI Pharmaceuticals, Inc is a United States–based specialty pharmaceutical company focused on the development, manufacturing and commercialization of generic and branded prescription drugs. The company operates as an end-to-end provider, offering services that range from active pharmaceutical ingredient (API) production and formulation development to finished dosage form manufacturing and packaging.

ANI’s product portfolio encompasses injectable and oral therapies across several therapeutic areas, including endocrinology, oncology, pain management and respiratory care.